臺灣健保癌症用藥事前審查實作指引
1.0.1 - release

This page is part of the 臺灣癌症用藥事前審查實作指引(TWPAS IG) (v1.0.1: Release) based on FHIR (HL7® FHIR® Standard) R4. This is the current published version. For a full list of available versions, see the Directory of published versions

: NHI-健保事前審查-給付適應症 - XML Representation

Active as of 2024-12-06

Raw xml | Download


<CodeSystem xmlns="http://hl7.org/fhir">
  <id value="nhi-apply-reason"/>
  <text>
    <status value="generated"/>
    <div xmlns="http://www.w3.org/1999/xhtml"><p class="res-header-id"><b>Generated Narrative: CodeSystem nhi-apply-reason</b></p><a name="nhi-apply-reason"> </a><a name="hcnhi-apply-reason"> </a><a name="nhi-apply-reason-en-US"> </a><p>This case-sensitive code system <code>https://twcore.mohw.gov.tw/ig/pas/CodeSystem/nhi-apply-reason</code> defines the following codes:</p><table class="codes"><tr><td style="white-space:nowrap"><b>Code</b></td><td><b>Display</b></td></tr><tr><td style="white-space:nowrap">C50P1<a name="nhi-apply-reason-C50P1"> </a></td><td>早期乳癌-未發生腋下淋巴結轉移</td></tr><tr><td style="white-space:nowrap">C50P2<a name="nhi-apply-reason-C50P2"> </a></td><td>早期乳癌-具腋下淋巴結轉移</td></tr><tr><td style="white-space:nowrap">C50R1<a name="nhi-apply-reason-C50R1"> </a></td><td>轉移性乳癌</td></tr><tr><td style="white-space:nowrap">C16R1<a name="nhi-apply-reason-C16R1"> </a></td><td>轉移性胃癌</td></tr><tr><td style="white-space:nowrap">P001<a name="nhi-apply-reason-P001"> </a></td><td>黑色素瘤</td></tr><tr><td style="white-space:nowrap">P011<a name="nhi-apply-reason-P011"> </a></td><td>非小細胞肺癌-SQ-2線</td></tr><tr><td style="white-space:nowrap">P012<a name="nhi-apply-reason-P012"> </a></td><td>非小細胞肺癌-Adeno-3線</td></tr><tr><td style="white-space:nowrap">P013<a name="nhi-apply-reason-P013"> </a></td><td>非小細胞肺癌-1線</td></tr><tr><td style="white-space:nowrap">P014<a name="nhi-apply-reason-P014"> </a></td><td>鱗狀非小細胞肺癌第一線用藥(併用化療)</td></tr><tr><td style="white-space:nowrap">P021<a name="nhi-apply-reason-P021"> </a></td><td>小細胞肺癌(併用化療)</td></tr><tr><td style="white-space:nowrap">P031<a name="nhi-apply-reason-P031"> </a></td><td>典型何杰金氏淋巴瘤</td></tr><tr><td style="white-space:nowrap">P041<a name="nhi-apply-reason-P041"> </a></td><td>泌尿道上皮癌-2線</td></tr><tr><td style="white-space:nowrap">P042<a name="nhi-apply-reason-P042"> </a></td><td>泌尿道上皮癌-1線</td></tr><tr><td style="white-space:nowrap">P043<a name="nhi-apply-reason-P043"> </a></td><td>局部晚期或轉移性泌尿道上皮癌之維持療法</td></tr><tr><td style="white-space:nowrap">P052<a name="nhi-apply-reason-P052"> </a></td><td>胃癌-1線(併用化療)</td></tr><tr><td style="white-space:nowrap">P061<a name="nhi-apply-reason-P061"> </a></td><td>腎細胞癌</td></tr><tr><td style="white-space:nowrap">P072<a name="nhi-apply-reason-P072"> </a></td><td>晚期肝細胞癌-1線(併用標靶bevacizumab)</td></tr><tr><td style="white-space:nowrap">P081<a name="nhi-apply-reason-P081"> </a></td><td>頭頸部鱗狀細胞癌第二線用藥</td></tr><tr><td style="white-space:nowrap">P082<a name="nhi-apply-reason-P082"> </a></td><td>頭頸部鱗狀細胞癌第一線用藥</td></tr><tr><td style="white-space:nowrap">P091<a name="nhi-apply-reason-P091"> </a></td><td>默克細胞癌</td></tr><tr><td style="white-space:nowrap">P101<a name="nhi-apply-reason-P101"> </a></td><td>食道鱗狀細胞癌</td></tr><tr><td style="white-space:nowrap">P111<a name="nhi-apply-reason-P111"> </a></td><td>惡性肋膜間皮瘤(ipilimumab併用nivolumab 120mg)</td></tr></table></div>
  </text>
  <url value="https://twcore.mohw.gov.tw/ig/pas/CodeSystem/nhi-apply-reason"/>
  <version value="1.0.1"/>
  <name value="NHIApplyReason"/>
  <title value="NHI-健保事前審查-給付適應症"/>
  <status value="active"/>
  <experimental value="false"/>
  <date value="2024-12-06"/>
  <publisher value="衛生福利部中央健康保險署"/>
  <contact>
    <name value="衛生福利部中央健康保險署"/>
    <telecom>
      <system value="url"/>
      <value value="https://www.nhi.gov.tw"/>
    </telecom>
  </contact>
  <description
               value="臺灣衛生福利部中央健康保險署「給付適應症」代碼，代碼出版日期：2024-12-06；資料所屬單位：臺灣衛生福利部中央健康保險署。"/>
  <caseSensitive value="true"/>
  <content value="complete"/>
  <count value="22"/>
  <concept>
    <code value="C50P1"/>
    <display value="早期乳癌-未發生腋下淋巴結轉移"/>
  </concept>
  <concept>
    <code value="C50P2"/>
    <display value="早期乳癌-具腋下淋巴結轉移"/>
  </concept>
  <concept>
    <code value="C50R1"/>
    <display value="轉移性乳癌"/>
  </concept>
  <concept>
    <code value="C16R1"/>
    <display value="轉移性胃癌"/>
  </concept>
  <concept>
    <code value="P001"/>
    <display value="黑色素瘤"/>
  </concept>
  <concept>
    <code value="P011"/>
    <display value="非小細胞肺癌-SQ-2線"/>
  </concept>
  <concept>
    <code value="P012"/>
    <display value="非小細胞肺癌-Adeno-3線"/>
  </concept>
  <concept>
    <code value="P013"/>
    <display value="非小細胞肺癌-1線"/>
  </concept>
  <concept>
    <code value="P014"/>
    <display value="鱗狀非小細胞肺癌第一線用藥(併用化療)"/>
  </concept>
  <concept>
    <code value="P021"/>
    <display value="小細胞肺癌(併用化療)"/>
  </concept>
  <concept>
    <code value="P031"/>
    <display value="典型何杰金氏淋巴瘤"/>
  </concept>
  <concept>
    <code value="P041"/>
    <display value="泌尿道上皮癌-2線"/>
  </concept>
  <concept>
    <code value="P042"/>
    <display value="泌尿道上皮癌-1線"/>
  </concept>
  <concept>
    <code value="P043"/>
    <display value="局部晚期或轉移性泌尿道上皮癌之維持療法"/>
  </concept>
  <concept>
    <code value="P052"/>
    <display value="胃癌-1線(併用化療)"/>
  </concept>
  <concept>
    <code value="P061"/>
    <display value="腎細胞癌"/>
  </concept>
  <concept>
    <code value="P072"/>
    <display value="晚期肝細胞癌-1線(併用標靶bevacizumab)"/>
  </concept>
  <concept>
    <code value="P081"/>
    <display value="頭頸部鱗狀細胞癌第二線用藥"/>
  </concept>
  <concept>
    <code value="P082"/>
    <display value="頭頸部鱗狀細胞癌第一線用藥"/>
  </concept>
  <concept>
    <code value="P091"/>
    <display value="默克細胞癌"/>
  </concept>
  <concept>
    <code value="P101"/>
    <display value="食道鱗狀細胞癌"/>
  </concept>
  <concept>
    <code value="P111"/>
    <display value="惡性肋膜間皮瘤(ipilimumab併用nivolumab 120mg)"/>
  </concept>
</CodeSystem>